Selective TNFR1 and TNFR2 Modulators for Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disease conditions associated with inflammation or ischaemia, such as renal and cardiovascular diseases, lack specificity in modulating tumour necrosis factor receptors (TNFRs), leading to non-targeted cellular responses and inadequate therapeutic outcomes.
Innovation Solution
Development of selective TNFR2 agonists and antagonists that preferentially stimulate or inhibit TNFR2 and TNFR1 signaling pathways, respectively, to promote specific cellular responses, including cell growth and proliferation, and tissue repair, using TNF polypeptides or antibodies with specific mutations and RNA interference techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective TNF blockade is used, then disease activity is controlled in rheumatoid arthritis, but therapeutic specificity is reduced and non-targeted cellular responses occur
Solution Approach 1:
The invention segments the TNF receptor system into two distinct pathways (TNFR1 and TNFR2) with different functional outcomes. By developing selective modulators that target individual receptors, the therapy can be tailored to specific disease mechanisms, resolving the contradiction between overall efficacy and specific targeting.
Solution Approach 2:
The patent applies local quality by creating receptor-specific modulators with distinct binding characteristics. TNFR1-selective and TNFR2-selective agents have different pharmacological properties that match the specific signaling requirements of each receptor pathway, enabling precise therapeutic control.
2Productivity
If selective TNFR2 agonists are used to promote cell growth and proliferation, then tissue repair is enhanced, but proliferation in inappropriate cases may be stimulated
Solution Approach 1:
The invention employs dynamic control by using agonists that can be activated or deactivated based on disease state. The selective TNFR2 agonists can be deployed when tissue repair is needed and withheld when inappropriate proliferation would occur, providing context-dependent therapeutic action.
Solution Approach 2:
The patent incorporates feedback mechanisms through selective modulation based on disease-specific signaling patterns. By monitoring TNFR2 activation and cellular responses, the therapy can be adjusted to promote proliferation only when beneficial, preventing harmful effects.
3Adaptability or versatility
If TNFR1 and TNFR2 signaling are differentially activated, then specific cellular responses are achieved, but complexity in signaling pathways increases
Solution Approach 1:
The invention extracts the essential signaling functions of TNFR1 and TNFR2 into separate, identifiable pathways. By isolating the distinct cellular responses (apoptosis for TNFR1, survival/proliferation for TNFR2), the complexity is managed through systematic analysis rather than overwhelming integration.
Solution Approach 2:
The patent manages signaling complexity by changing the pharmacological parameters of TNF interaction. Selective agonists and antagonists modify binding affinity and activation thresholds, transforming the complex signaling network into controllable, discrete responses that can be independently regulated.
Data Source
AI summary
This invention relates to the identification and characterization of specific cellular responses which are associated with tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 1 (TNFR2). Selective modulation of these tumor necrosis factor receptors (TNFRs) Selective modulations of these responses may be useful in the promotion or inhibition of cell growth, for example, in the treatment of disease conditions, including cardiovascular and kidney diseases. Therapeutic methods employed selective TNFR1 and TNFR2 modulators are provided, along with screening methods for the identification of selective TNFR1 and TNFR2 modulators useful in such methods.